glp-1 news today october 23 2025

glp-1 news today october 23 2025 President Trump announced that Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for weight management indications for people with obesity. Our senior staff writer Kristen Monaco breaks it down on the latest Looming GLP-1 drug patent expirations

Name: glp-1 news today october 23 2025 President Trump announced that Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for weight management indications for people with obesity. Our senior staff writer Kristen Monaco breaks it down on the latest Looming GLP-1 drug patent expirations
Brand: actil.am
SKU: 40982156400
Price: 24.42 USD
Availability: InStock
Rating: 4.1926 (9 reviews)

SKU: 40982156400

4.2

USD24.42 USD55.42

Pay in 4 interest-free payments of $6.11 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 24 - Aug 29

Description

Diuretics and SGLT2 inhibitors can exacerbate fluid and electrolyte losses, whilst statins are independently associated with muscle-related symptoms

Available from: Hall K

J.LuciaM

18 The SYNERGY-NASH (A Study of Tirzepatide [LY3298176] in Participants With Nonalcoholic Steatohepatitis) trial, 19 a phase 2b dose-finding study, randomized 190 patients with biopsy-confirmed MASH and stage 2 or 3 fibrosis to receive weekly injections of the GLP-1 and GIP dual agonist tirzepatide 5 mg, 10 mg, or 15 mg or placebo for 52 weeks